Academic Health Center

Center for Drug Design

Steven E. Patterson, PhD

ahCCDD2 - Content - Image - Steve Patterson_180x222px

Academic Title

Professor
Center for Drug Design Advisory Committee

Education

Bachelor's
Georgia State University, GA (1992)
Ph.D.
Georgia State University, GA (1995)

Contact Info

Email
patte219@umn.edu

Phone
612-625-7962

Office Address

7-216 Phillips Wangensteen Building
516 Delaware Street SE
Minneapolis, MN 55455

Mailing Address

516 Delaware Street SE
MMC 204
Minneapolis, MN 55455

 

Patterson Group

 

Research Interests

Anti-microbial Drugs

Over the years, bacteria, fungi and protozoa have increasingly developed resistance to traditional antibiotics. In particular fungi and protozoa are recognized as emerging problems; in the past 25 years the number of life threatening infections caused by these organisms due to their resistance to traditional drugs has been growing. Research on new medicines to fight these infections is a focus of our labs. In collaboration with Chris Dykstra and Scott Franzblau we are targeting enzymes in these organisms that synthesize necessary components of their cell walls. The cell wall is an attractive target since it is required by the pathogens for growth, but has no counterpart in humans and other mammals.

Cancer Therapy

The simplest description of cancer is uncontrolled cell growth. In collaboration with Lee Wattenberg, Kris Pankiewicz and Dan Billadeau our lab is interested in stopping growth of tumors by causing tumor cells to differentiate or by interfering with cell signaling pathways involved with cell growth. This based on the concept that cancer cells are normal cells that are trapped in an immature (or less differentiated) state, where they lack the ability to control their own growth. We have designed and synthesized a class of molecules that causes differentiation of many types of cancer cells. This does not destroy the cancer cells, but instead causes them to mature into cells that can regulate their own growth. This approach is less toxic than conventional chemotherapy, which attempts to kill the cells completely.

Antiviral Therapy

In collaboration with Lou Mansky we are investigating the effect of novel combination therapy and its potential for clinical use as treatment for viral infections such as HIV and Hepatitis.

Cyanide Antidotes

Cyanide is a well known toxin with potential as an international threat, a weapon of mass destruction and an accidental hazard through industrial exposure, medical crisis or smoke inhalation. Current treatments for cyanide poisoning are slow acting and can have serious life threatening side effects. In collaboration with Herb Nagasawa and Bob Vince we are developing a series of andidotes that use a ubiquitous enzyme that converts cyanide to a non-toxic substance. We have shown that our antidotes are more effective than the current treatments. In addition, our treatments work prophylactically. Currently we are working to expand our series of antidotes, to improve their efficacy in reversing cyanide toxicity, and to move these potential treatments into clinical trials.

Synthetic Methods

Because many drug design projects involve molecules known as nucleosides, nucleotides, and carbohydrates, our group is interested in finding improved ways to make these molecules.

Publications

Recent Publications (For detailed publication list: Click Here)

Determination of 3-mercaptopyruvate in plasma by high performance liquid chromatography tandem mass spectrometry. Stutelberg MW, Vinnakota, CV Mitchell BL, Monteil AR, Patterson SE, and Logue BA. J. Chromatog. B (in press).

Characterization of permeability, stability and anti-HIV-1 activity of decitabine and gemcitabine divalerate prodrugs. Clouser CL, Bonnac L, Mansky LM, Patterson SE. Antivir. Chem. Chemother. 2013; doi: 10.3851/IMP2682. [Epub ahead of print] Abstract

Polyoxin and Nikkomycin Analogs: Recent Design and Synthesis of Novel Peptidyl Nucleosides. Jackson KE, Pogula PK, and Patterson SE. Heterocycl. Commun. (in press).

Structure-Activity Relationships and Design of Viral Mutagens and Application to Lethal Mutagenesis. Bonnac LF, Mansky LM, Patterson SE. J. Med. Chem. 2013 Aug 5;Ahead of Print; doi: 10.1021/jm400653j. Abstract

AHCCDD2-Image-KPankiewicz_TOCGraphic1_Border

Cyanide Antidotes for Mass Casualties: Water-Soluble Salts of the Dithiane (Sulfanegen) from 3-Mercaptopyruvate for Intramuscular Administration. Patterson SE, Monteil AR, Cohen JF, Crankshaw DL, Vince R, Nagasawa, HT. J. Med. Chem. 2013;56:1346-49. Abstract

AHCCDD2-Image-SPatterson_TOCGraphic2_Border

Seasonal pasture myopathy/atypical myopathy in North America associated with ingestion of hypoglycin A within seeds of the box elder tree. Valberg SJ, Sponseller BT, Hegeman AD, Earing J, Bender JB, Martinson KL, Patterson SE, Sweetman L. Equine Vet. J. 2013;45(4):419-26. Abstract

Back to the future: revisiting HIV-1 lethal mutagenesis. Dapp MJ, Patterson SE, Mansky LM. Trends Microbiol. 2013;21(2):56-62. Abstract

IP-FCM measures physiologic protein-protein interactions modulated by signal transduction and small-molecule drug inhibition. Smith SEP, Bida AT, Davis TR, Sicotte H, Patterson, SE, Gil D, Schrum AG. PLoS One. 2012 Sep;7(9):e45722. Abstract

Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabine. Clouser CL, Chauhan J, Bess MA, Oploo, JL, Zhou D, Dimick-Gray S, Mansky, LM, Patterson SE. Bioorg. Med. Chem. Lett. 2012 Nov 1;22(21):6642-6646. Abstract

Cyanide Toxicity in Juvenile Pigs and Its Reversal by a New Prodrug, Sulfanegen Sodium. Belani KG, Singh H, Beebe DS, George P, Patterson SE, Nagasawa HT, Vince R. Anesth Analg. 2012 Mar;114(5): 956-61. Abstract

  • ©2013 Regents of the University of Minnesota. All rights reserved.
  • The University of Minnesota is an equal opportunity educator and employer
  • Last modified on December 6, 2013